Clonexpress, Inc

Clonexpress has developed a novel technology platform to generate patient-specific differentiated cell types by epigenetic induction. Clonexpress has developed patient specific pancreatic beta cells, hepatocytes, and dopaminergic neuron cells from adult human fibroblasts and peripheral blood mononuclear cells (three issued patents- US9,029,141B2,US9,394,525 and US10,100,280B2). Clonexpress has developed human pancreatic beta islets cell line (glucose responsive insulin release similar to primary beta cells) and hepatocyte (metabolism qualified ) cell lines. These cell lines are very close to normal cells and are available for licensing or purchase for drug discovery and toxicology applications. Clonexpress has recently developed a human microglial cell line available for licensing or purchase. Custom development of tumor cell lines from tumor samples provided by the client -successfully developed multiple myeloma and other cell types from tumor samples provided by clients Custom cell line development of cell lines using primary cells provided by client (both human and non-human) for research use. Clonexpres has discovered a common growth control mechanism in different types of cancers, and such growth control mechanism is not present in different normal cells (fibroblasts and mesenchymal cells) capable of continuous growth in culture. This is a totally new paradigm to develop new class of drugs with minimal or no side effects to cure cancer and metastasis. Clonexpress has developed a very sensitive assay to identify the target. Clonexpress is actively seeking funding /partnership opportunities to use this technology to find a cure for different types of cancer. Clonexpress also provides human central nervous system (CNS) primary cells - neuronal progenitor cells, dopaminnergic neuron cells, astrocytes, and microglial cells, diffetrent endothelial cells, human fibroblasts, bone marrow stromal cells, liver mesenchymal cells to for research.